News Updates
More Articles
- WHO, Korea to build biomanufacturing training hub
- UK grants funding to Pictura Bio for AI-guided testing
- EMA committee proposes retraction of SCD drug's approval
- J&J seeks EMA approval of cilta-cel as second-line drug
- Moderna registers unit in China in search of opportunities
Sanofi announces price cut for two insulin products
Sanofi announced that it will reduce the list price of its most-prescribed insulin product Lantus in the US by 78% and Apidra by 70%, with out-of-pocket monthly costs to be capped at $35 for those with private insurance. The price change will be effective Jan. 1. CNBC (3/16)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!